ReviewBritish journal of clinical pharmacology2019
Susceptibility to adverse drug reactions.
Review in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Pooled it
- Article
- Article
- Potential Drug Dose-Specific Adverse Three-Drug Combinations: A US Insurance Claims Data-Based Study.Pharmacoepidemiology and drug safety · 2025Article
- Medications, epilepsy and climate change: Added layers of complexity.British journal of clinical pharmacology · 2025Review
- Adverse Drug Reactions in Pregnant People with Hypertension and/or Diabetes: Temporal Profile and Associated Factors.The Canadian journal of hospital pharmacy · 2025Article
- Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database.Frontiers in pharmacology · 2024Article
- Article
- Drug dosing in children with obesity: a narrative updated review.Italian journal of pediatrics · 2022Review
- Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.British journal of clinical pharmacology · 2022Review
- Statin doses after acute coronary syndrome.Australian prescriber · 2022Article
- Risk factors for adverse drug reactions associated with clopidogrel therapy.Open medicine (Warsaw, Poland) · 2022Article
- Commentary on Health service use and costs associated with fluoroquinolone-related tendon injuries.Pharmacology research & perspectives · 2021Article
- Article
- On precision dosing of oral small molecule drugs in oncology.British journal of clinical pharmacology · 2021Review
- Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine.Frontiers in pharmacology · 2021Review
- The rationale of dose-response curves in selecting cancer drug dosing.British journal of clinical pharmacology · 2019Review
- Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?British journal of clinical pharmacology · 2019Article
- Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50.British journal of clinical pharmacology · 2019Review
- Susceptibility to adverse drug reactions.British journal of clinical pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmacological effects of a drug depend on its concentration at the site of action, and therefore on the concentration in blood and on the dose. The relationship between the concentration or dose and the corresponding effect can usually be represented mathematically as a rectangular hyperbola; when effect is plotted against log concentration or log dose, the curve is sigmoidal. Inevitably, the effect size and the doses causing benefit and harm will differ among individuals, since they are biological phenomena: some individuals are more likely than others to suffer harm at any given dose. Some harmful effects can occur at much lower doses than those used in therapeutics; that is, the log dose-response curve for harm lies far to the left of the log dose-response curve for benefit. Those who suffer such reactions are hypersusceptible. When the dose-response curves for harm and therapeutic effect are in the same range, dose cannot separate the harmful effects from the therapeutic effects, and adverse reactions are collateral. Toxic effects occur when harmful doses are above the doses needed for benefit. In this review we consider factors that influence a subject's susceptibility to adverse drug reactions. Determinants of susceptibility include Immunological, Genetic, demographic (Age and Sex), Physiological and Exogenous factors (drug-drug interactions, for example), and Diseases and disorders such as renal failure, giving the mnemonic I GASPED. Some susceptibility factors are discrete (for example, all-or-none) and some are continuous; susceptibility can therefore be discrete or continuous; and the factors can interact to determine a person's overall susceptibility to harm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.